Your browser doesn't support javascript.
loading
Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip.
van der Aar, Ellen; Deckx, Henri; Dupont, Sonia; Fieuw, Ann; Delage, Stephane; Larsson, Staffan; Struglics, André; Lohmander, L Stefan; Lalande, Agnes; Leroux, Emilie; Amantini, David; Passier, Paul.
Afiliação
  • van der Aar E; Galapagos NV, Mechelen, Belgium.
  • Deckx H; Galapagos NV, Mechelen, Belgium.
  • Dupont S; Galapagos SASU, Romainville, France.
  • Fieuw A; Galapagos NV, Mechelen, Belgium.
  • Delage S; Galapagos SASU, Romainville, France.
  • Larsson S; Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden.
  • Struglics A; Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden.
  • Lohmander LS; Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden.
  • Lalande A; Institut de Recherches Internationales Servier (I.R.I.S.), Servier, Suresnes, France.
  • Leroux E; Institut de Recherches Internationales Servier (I.R.I.S.), Servier, Suresnes, France.
  • Amantini D; Galapagos SASU, Romainville, France.
  • Passier P; Galapagos SASU, Romainville, France.
Clin Pharmacol Drug Dev ; 11(1): 112-122, 2022 01.
Article em En | MEDLINE | ID: mdl-34859612
ABSTRACT
GLPG1972/S201086 is a disintegrin and metalloproteinase with thrombospondin motif-5 (ADAMTS-5) inhibitor in development as an osteoarthritis disease-modifying therapy. We report the safety, tolerability, pharmacokinetics, and pharmacodynamics (turnover of plasma/serum ARGS-aggrecan neoepitope fragments [ARGS]) of GLPG1972 in 3 randomized, double-blind, placebo-controlled phase 1 trials. Study A, a first-in-human trial of single (≤2100 mg [fasted] and 300 mg [fed]) and multiple (≤1050 mg once daily [fed]; 14 days) ascending oral (solution) doses, investigated GLPG1972 in healthy men (N = 41; NCT02612246). Study B investigated multiple ascending oral (tablet) doses of GLPG1972 (≤300 mg once daily [fed]; 4 weeks) in male and female participants with osteoarthritis (N = 30; NCT03311009). Study C investigated single (Japanese ≤1500 mg; White 300 mg [fasted]) and multiple (Japanese, ≤1050 mg once daily; White, 300 mg once daily [fed]; 14 days) ascending oral (tablet) doses of GLPG1972 in healthy Japanese and White men (N = 88). The pharmacokinetic profile of GLPG1972 was similar between healthy participants and participants with osteoarthritis, with low to moderate interindividual variability. GLPG1972 was rapidly absorbed (median time to maximum concentration, 4 hours), and eliminated with a mean apparent terminal elimination half-life of ≈10 hours. Steady state was achieved within 2 days of dosing, with minimal accumulation. Steady-state plasma exposure after 300 mg of GLPG1972 showed no or minor differences between populations. Area under the plasma concentration-time curve (56.8-67.6 µg · h/mL) and time to maximum concentration (4 hours) were similar between studies. Urinary excretion of GLPG1972 (24 hours) was low (<11%). Multiple dosing significantly reduced ARGS levels vs baseline at all time points for all doses vs placebo. GLPG1972 was generally well tolerated at all doses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite do Joelho / Proteína ADAMTS5 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite do Joelho / Proteína ADAMTS5 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article